Aeolus Pharmaceuticals reports Barda's exercises of USD3m in additional contract funding for development of AEOL 10150 for Acute Radiation Syndrome
M2 - Mon Jun 29, 3:19AM CDT
Biotechnology company Aeolus Pharmaceuticals (OtherOTC:AOLS) disclosed on Friday the exercise of USD3m in additional contract options for AEOL 10150 by Biomedical Advanced Research and Development Authority (BARDA) under the USD118m advanced research and development contract.
Barda Exercises $3 MM in Additional Contract Funding for Development of AEOL 10150 as Treatment for Acute Radiation Syndrome
Marketwired - Fri Jun 26, 7:00AM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats in partnership with the US Government, announced today that the Biomedical Advanced Research and Development Authority (BARDA) exercised $3 million in additional contract options under its advanced research and development contract for AEOL 10150. BARDA is a division of the U.S. Department of Health and Human Services that manages the advanced development and purchase of medical countermeasures for public health threats.
Gastrointestinal Radiation Toxicity Pipeline Review, H1 2015 - 3 Companies & 5 Drug Profiles
M2 - Mon Jun 08, 10:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9xrv6c/gastrointestinal) has announced the addition of the "Gastrointestinal Radiation Toxicity - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gastrointestinal Radiation Toxicity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastrointestinal Radiation Toxicity and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aeolus Pharmaceuticals, Inc. - Avaxia Biologics, Inc. - Soligenix, Inc. Drug Profiles - 2A2 - AEOL-10150 - AVX-470 - m2A2 - SGX-202 For more information visit http://www.researchandmarkets.com/research/9x...intestinal
Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2015
M2 - Tue Jun 02, 8:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cp3333/idiopathic) has announced the addition of the "Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Pulmonary Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AdAlta Pty Ltd. - Aeolus Pharmaceuticals, Inc. - AnaptysBio, Inc. - Auspex Pharmaceuticals, Inc. - Biogen Idec Inc. - Bioneer Corporation - BiOrion Technologies B.V. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Carolus Therapeutics, Inc. - Celgene Corporation - Chong Kun Dang Pharmaceutical Corp. - Compugen Ltd. - F. Hoffmann-La Roche Ltd. - FibroGen, Inc. - Five Prime Therapeutics, Inc. - GenKyoTex S.A. - Gilead Sciences, Inc. - GlaxoSmithKline plc - HanAll Biopharma Co., Ltd. - Histocell S.L. - iBio, Inc. - ImmuneWorks, LLC - Inventiva SAS - Kadmon Corporation, LLC - Kasiak Research Pvt. Ltd. - Kyorin Pharmaceutical Co., Ltd. - Lanthio Pharma B.V. - LTT Bio-Pharma Co., Ltd. - MedImmune, LLC - Moerae Matrix, Inc. - MSM Protein Technologies, Inc. - Pacific Therapeutics Ltd. - Pharmaxis Limited - Progenra, Inc. For more information visit http://www.researchandmarkets.com/research/cp3333/idiopathic
BIIB: 388.23 (-11.06), ASPX: 100.96 (unch), BMY: 69.27 (+1.38), GSK: 42.45 (+0.65), GILD: 113.74 (+0.38), CGEN: 6.63 (+0.06), IBIO: 0.86 (+0.01), FGEN: 22.82 (+0.58), CELGZ: 2.15 (+0.14), FPRX: 26.01 (+0.37)
Aeolus Pharmateucticals to Present at LD Micro Invitational Conference
Marketwired - Thu May 28, 6:30AM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats in partnership with the US Government, announced today that David C. Cavalier, Chairman and Chief Financial Officer, will present at the LD Micro Invitational Conference on Tuesday, June 2nd, 2015 at 11:30 AM PDT (2:30 PM EDT) at the Luxe Sunset Boulevard Hotel in Los Angeles. Mr. Cavalier will provide an overview of Aeolus' development programs with a focus on the Company's progress under its contract with the Biomedical Advanced Research and Development Authority ("BARDA"
Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Pipeline Review 2015
M2 - Wed May 27, 11:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rz8t2h/radiation) has announced the addition of the "Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aeolus Pharmaceuticals, Inc. - Bolder Biotechnology, Inc. - Cantex Pharmaceuticals, Inc. - Cellerant Therapeutics, Inc. - Cleveland BioLabs, Inc. - Gamida Cell Ltd. - Humanetics Corporation - Meabco A/S - NeoStem, Inc. - Neumedicines Inc. - Onconova Therapeutics, Inc. - Piramal Enterprises Limited - Pluristem Therapeutics Inc. - Priaxon AG - ProCertus BioPharm Inc. - RDD Pharma Ltd. - RxBio, Inc. - Soligenix, Inc. - Terapio Corporation - Tonix Pharmaceuticals Holding Corp. For more information visit http://www.researchandmarkets.com/research/rz8t2h/radiation
TNXP: 8.22 (-0.36), PSTI: 2.40 (+0.03), NBS: 2.25 (-0.09), ONTX: 2.51 (-0.09), CBLI: 3.78 (+0.17)
Aeolus Announces Second Quarter Fiscal Year 2015 Financial Results
Marketwired - Fri May 15, 3:53PM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with significant funding from the US Government, announced today financial results for the three and six months ended March 31, 2015.
Aeolus Announces Complete Results From Successful Study Showing AEOL 10150 Doubles Survival Rate Following Lung Damage Caused by Acute Radiation Exposure
Marketwired - Mon May 04, 6:30AM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
Aeolus Pharmaceuticals, Inc. - Product Pipeline Review - 2015
M2 - Fri Apr 17, 2:46AM CDT
This report provides comprehensive information on the current therapeutic developmental pipeline of Aeolus Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
Aeolus Files Patent Application and Completes Licensure of New Series of Compounds to Treat Infectious and Inflammatory Disease
Marketwired - Wed Apr 15, 7:01AM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with significant funding from the US Government, announced today that it has filed a provisional patent application with the United States Patent Office for a new series of compounds demonstrating anti-microbial and anti-inflammatory action. The compounds were developed by Brian J. Day, PhD at National Jewish Health in Denver, Colorado as a result of an Aeolus-sponsored research grant. Aeolus also announced that it has obtained a worldwide, exclusive license to develop the compounds from National Jewish Health.
Aeolus Receives Notice of Allowance From Israeli Patent Office for Use of AEOL 10150 and Other Aeolus Compounds to Treat Injury From Exposure to Alkylating Agents Such as Sulfur Mustard Gas
Marketwired - Tue Mar 31, 7:03AM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with significant funding from the US Government, announced today that it has received a Notice of Allowance from the Israeli Patent Office for application number 209435, "Methods for Treating Injury Associated with Exposure to an Alkylating Species." The patent covers Aeolus' lead compound, AEOL 10150 as well as other metalloporphyrins under development by the Company. Alkylating agents include chemical gas agents such as sulfur mustard gas.
Aeolus wins US FDA's orphan drug designation for AEOL 10150 for treating idiopathic pulmonary fibrosis
M2 - Wed Mar 18, 6:55AM CDT
Biotechnology company Aeolus Pharmaceuticals (OtherOTC:AOLS) reported on Tuesday the receipt of orphan drug designation for AEOL 10150 for treatment of idiopathic pulmonary fibrosis from from the Office of Orphan Products Development at the US Food & Drug Administration (FDA).
Aeolus Pharma antioxidant an Orphan Drug for lung disease
Seeking Alpha - at Seeking Alpha - Tue Mar 17, 12:38PM CDT
Aeolus Receives Orphan Drug Designation From US FDA for AEOL 10150 for Treatment of Idiopathic Pulmonary Fibrosis
Marketwired - Tue Mar 17, 10:46AM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with significant funding from the US Government, announced today that it has received notice from the Office of Orphan Products Development at the U.S. Food & Drug Administration (FDA) granting Orphan Drug Designation for AEOL 10150 "for treatment of idiopathic pulmonary fibrosis." Orphan Drug Designation entitles the sponsor to a seven-year marketing exclusivity period, clinical protocol assistance with the FDA, as well as federal grants and tax credits.